Intensity Therapeutics - INTS Income before deduction of interest, taxes and amortization
The Intensity Therapeutics (INTS) EBITDA chart is based on management's consistent execution of clinical plans. High authority in oncology, driven by direct tumor drug delivery methods, and complete independence from GDP phases ensure business resilience. This trend is confirmed by the fact that 0.00 forms the current metric, clearly demonstrating the company's real cash flow.
Intensity Therapeutics, Inc. - analytical breakdowns and key metrics (INTS)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Intensity Therapeutics|INTS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Intensity Therapeutics Inc|INTS - Company Debts|Debt to Book Value Ratio Intensity Therapeutics|INTS - Company Long-Term Debt|Short-Term Debt Intensity Therapeutics|Critical Liquidity intensitytherapeutics.com
- company profitability and valuation multiples indicators:
INTS - Net Income|Future Net Profit Intensity Therapeutics|INTS - P/E Multiple|Future Price to Earnings Multiple Intensity Therapeutics Inc|INTS - PEG Multiple|Company Value to EBITDA Intensity Therapeutics|INTS - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Intensity Therapeutics|INTS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth intensitytherapeutics.com|INTS - Earnings per share growth in current year|Net earnings per share change forecast for next year Intensity Therapeutics
Analysis of all company metrics:Intensity Therapeutics - INTS
Developing the DATH platform for cancer therapy requires colossal expenditures, making the analysis of operating cash flow critical. This EBITDA chart captures the actual cash generated by the business excluding accounting adjustments, allowing for an assessment of Intensity Therapeutics (INTS) resilience to recession and its ability to fund R&D investments without a critical dependence on external borrowings.
Competitors of Intensity Therapeutics (INTS)
NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (Innate Pharma S.A) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization INKT (MiNK)|Company profit before taxes, interest and amortization HOWL|Operating profit EBITDA IMMX (Immix Biopharma)|Income before deduction of interest, taxes and amortization ALXO|Cue Biopharma, Inc. - Operating profit EBITDA|Profit before interest, taxes and amortization PDS Biotechnology|sonnetbio.com (SONN) - Profit before payment of interest, taxes and amortization|MAIA Bio - Income before deduction of interest, taxes and amortization|LIMN (Liminatus Pharma) - Operating profit EBITDA|Operating profit EBITDA Lava Tx|Profit before payment of interest, taxes and amortization NextCure (NXTC)|LPTX: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|Gritstone Bio - Operating profit EBITDA|Operating income before deduction of amortization kinetabio.com KA|NexImmune (NEXI) - Profit before payment of interest, taxes and amortization|Operating profit before amortization TSBX|Operating profit before deduction of amortization VCNX|HARP (Harpoon Therapeutics Corp) - Company profit before taxes, interest and amortization
